North AmericaJMCountry Report

Psychedelic Research in

Jamaica

Jamaica has a relatively permissive context for psilocybin-containing mushrooms compared with many countries, alongside a more conventional controlled-drug framework for other psychedelics. Publicly available clinical activity is limited, but Jamaica has been referenced in recent academic and registry material as a site of psilocybin-related research interest, and the country's health authorities have emphasised monitoring of new psychoactive substances and drug control.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Jamaica.

  • 1

    Jamaica's public drug-control framework is clear, but psilocybin-specific scheduling is not spelled out in the Ministry page reviewed, which leaves some residual ambiguity in how the permissive market is implemented in practice.

  • 2

    The country's visible psychedelic research footprint is small in the public record, consistent with Blossom's one linked psilocybin study and no active linked trials.

  • 3

    Recent Ministry communications on drug surveillance suggest a policy focus on monitoring emerging substances rather than liberalising broader psychedelic access.

  • 4

    Academic material from Jamaican-affiliated authors continues to frame Jamaica as a potentially useful setting for regulated psilocybin research, but this is an interpretation of research commentary rather than a legal authorisation.

  • 5

    The public evidence supports a distinction between informal/commercial psilocybin retreat activity and formal medical access, with the latter not clearly documented as a national pathway in the sources reviewed.

Research Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Jamaica.

Active trials
0

None marked active

Total trials
1

Country-linked records

Stakeholders
12

Linked organisations

Events
0

No linked events

Top Compounds

  • Psilocybin(1)

Top Study Topics

  • Anxiety Disorders(1)

Medical Access Snapshot

Jamaica is widely known for a permissive stance toward psilocybin-containing mushrooms (they are not scheduled under Jamaican law) and hosts commercial retreats and producers. Other classical and synthetic psychedelics (MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X) fall under Jamaica's general Dangerous Drugs regulatory framework and are treated as controlled/illegal except insofar as they are used in approved clinical research. Ketamine is used in Jamaica as an established anesthetic in healthcare settings and can be prescribed; however, licensed esketamine...

View trials→View stakeholders→Open access guide→

Regulatory Status

Jamaica's Ministry of Health and Wellness lists the Dangerous Drugs Act and associated regulations as core controls for narcotic and psychotropic substances, while also noting that the Act covers monitoring and control of illicit drugs and psychotropic substances such as ganja. Public sources reviewed here do not show an explicit national scheduling statement for psilocybin in the same way, so the practical position on psilocybin mushrooms appears more permissive than the general controlled-drug framework, but exact legality and any permitted access pathways should be treated cautiously and verified case by case. Clinical or hospital use of other psychedelics appears confined to approved research settings; Jamaica has also continued to build drug-monitoring capacity, including an early warning system on drugs.

Country Details

Region
North America
Last updated
4 May 2026

Country Report

Medical Only (Private)

Medical Access and Reimbursement

Jamaica is widely known for a permissive stance toward psilocybin-containing mushrooms (they are not scheduled under Jamaican law) and hosts commercial retreats and producers. Other classical and synthetic psychedelics (MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X) fall under Jamaica's general Dangerous...

Open access guide →
All Countries→Clinical Trials→Stakeholders→Events→Research Papers→

Clinical Trials

Active and completed clinical trials investigating psychedelic-assisted therapies in Jamaica.

View all trials →
WithdrawnPhase II

Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults

Started